909 related articles for article (PubMed ID: 16282176)
1. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Mellinghoff IK; Wang MY; Vivanco I; Haas-Kogan DA; Zhu S; Dia EQ; Lu KV; Yoshimoto K; Huang JH; Chute DJ; Riggs BL; Horvath S; Liau LM; Cavenee WK; Rao PN; Beroukhim R; Peck TC; Lee JC; Sellers WR; Stokoe D; Prados M; Cloughesy TF; Sawyers CL; Mischel PS
N Engl J Med; 2005 Nov; 353(19):2012-24. PubMed ID: 16282176
[TBL] [Abstract][Full Text] [Related]
2. Response of glioblastomas to EGFR kinase inhibitors.
Lassman AB; Abrey LE; Gilbert MR
N Engl J Med; 2006 Feb; 354(5):525-6; author reply 525-6. PubMed ID: 16452568
[No Abstract] [Full Text] [Related]
3. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS
Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Haas-Kogan DA; Prados MD; Tihan T; Eberhard DA; Jelluma N; Arvold ND; Baumber R; Lamborn KR; Kapadia A; Malec M; Berger MS; Stokoe D
J Natl Cancer Inst; 2005 Jun; 97(12):880-7. PubMed ID: 15956649
[TBL] [Abstract][Full Text] [Related]
5. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma multiforme and the epidermal growth factor receptor.
Friedman HS; Bigner DD
N Engl J Med; 2005 Nov; 353(19):1997-9. PubMed ID: 16282174
[No Abstract] [Full Text] [Related]
7. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Lv S; Teugels E; Sadones J; De Brakeleer S; Duerinck J; Du Four S; Michotte A; De Grève J; Neyns B
Int J Oncol; 2012 Sep; 41(3):1029-35. PubMed ID: 22752145
[TBL] [Abstract][Full Text] [Related]
8. Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
Custodio A; Calles A; Pérez-Segura P
Clin Transl Oncol; 2010 Apr; 12(4):310-4. PubMed ID: 20462843
[TBL] [Abstract][Full Text] [Related]
9. Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status.
Navarro L; Gil-Benso R; Megías J; Muñoz-Hidalgo L; San-Miguel T; Callaghan RC; González-Darder JM; López-Ginés C; Cerdá-Nicolás MJ
Neuroscience; 2015 Jun; 297():243-51. PubMed ID: 25869624
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
Lee JC; Vivanco I; Beroukhim R; Huang JH; Feng WL; DeBiasi RM; Yoshimoto K; King JC; Nghiemphu P; Yuza Y; Xu Q; Greulich H; Thomas RK; Paez JG; Peck TC; Linhart DJ; Glatt KA; Getz G; Onofrio R; Ziaugra L; Levine RL; Gabriel S; Kawaguchi T; O'Neill K; Khan H; Liau LM; Nelson SF; Rao PN; Mischel P; Pieper RO; Cloughesy T; Leahy DJ; Sellers WR; Sawyers CL; Meyerson M; Mellinghoff IK
PLoS Med; 2006 Dec; 3(12):e485. PubMed ID: 17177598
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
Liffers K; Kolbe K; Westphal M; Lamszus K; Schulte A
Target Oncol; 2016 Feb; 11(1):29-40. PubMed ID: 26032687
[TBL] [Abstract][Full Text] [Related]
13. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.
Sarkaria JN; Yang L; Grogan PT; Kitange GJ; Carlson BL; Schroeder MA; Galanis E; Giannini C; Wu W; Dinca EB; James CD
Mol Cancer Ther; 2007 Mar; 6(3):1167-74. PubMed ID: 17363510
[TBL] [Abstract][Full Text] [Related]
14. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Kinsella P; Howley R; Doolan P; Clarke C; Madden SF; Clynes M; Farrell M; Amberger-Murphy V
Exp Cell Res; 2012 Mar; 318(5):641-52. PubMed ID: 22285130
[TBL] [Abstract][Full Text] [Related]
15. Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma.
Toth J; Egervari K; Klekner A; Bognar L; Szanto J; Nemes Z; Szollosi Z
Pathol Oncol Res; 2009 Jun; 15(2):225-9. PubMed ID: 18752056
[TBL] [Abstract][Full Text] [Related]
16. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.
Pollack IF; Hamilton RL; James CD; Finkelstein SD; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL;
J Neurosurg; 2006 Nov; 105(5 Suppl):418-24. PubMed ID: 17328268
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib.
Halatsch ME; Löw S; Hielscher T; Schmidt U; Unterberg A; Vougioukas VI
Anticancer Res; 2008; 28(6A):3725-8. PubMed ID: 19189656
[TBL] [Abstract][Full Text] [Related]
18. Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro.
Festuccia C; Gravina GL; Biordi L; D'Ascenzo S; Dolo V; Ficorella C; Ricevuto E; Tombolini V
Prostate; 2009 Oct; 69(14):1529-37. PubMed ID: 19562712
[TBL] [Abstract][Full Text] [Related]
19. EGFR tyrosine kinase domain mutations in human gliomas.
Marie Y; Carpentier AF; Omuro AM; Sanson M; Thillet J; Hoang-Xuan K; Delattre JY
Neurology; 2005 Apr; 64(8):1444-5. PubMed ID: 15851741
[TBL] [Abstract][Full Text] [Related]
20. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Bax DA; Gaspar N; Little SE; Marshall L; Perryman L; Regairaz M; Viana-Pereira M; Vuononvirta R; Sharp SY; Reis-Filho JS; Stávale JN; Al-Sarraj S; Reis RM; Vassal G; Pearson AD; Hargrave D; Ellison DW; Workman P; Jones C
Clin Cancer Res; 2009 Sep; 15(18):5753-61. PubMed ID: 19737945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
